QIAGEN announced a new collaboration with NVIDIA aimed at integrating accelerated computing and artificial intelligence into drug discovery workflows, a move the company says could help pharmaceutical and biotechnology researchers better identify therapeutic targets, biomarkers and biological insights from increasingly complex datasets.
The announcement was made at the BIO-IT World Conference & Expo in Boston, where QIAGEN said its Digital Insights bioinformatics business will integrate NVIDIA accelerated computing and the NVIDIA BioNeMo platform with its curated biomedical knowledge bases and bioinformatics expertise.
The collaboration is intended to improve how researchers use AI in drug discovery by helping them navigate large and complex biological datasets and assess whether machine-generated insights are scientifically meaningful and biologically credible.
Drug discovery often requires researchers to analyze large volumes of interconnected information spanning genes, diseases, molecular pathways, compounds and clinical evidence. However, growing data complexity has made it increasingly difficult for scientists to determine which findings are relevant and supported by evidence.
To address these challenges, QIAGEN and NVIDIA are developing graph-based artificial intelligence systems designed to apply retrieval and reasoning techniques over biomedical knowledge graphs. According to the companies, this approach allows researchers to explore biological relationships more effectively and could support the emergence of multi-step, agentic workflows capable of improving decision-making during drug development.
QIAGEN said the technology will integrate with its Discovery Platform, which combines curated information across genes, diseases, pathways, compounds and clinical evidence to provide scientific context for researchers.
The company plans to incorporate graph-based retrieval AI technologies using frameworks such as PyTorch Geometric and GPU-accelerated GraphRAG systems, delivered through NVIDIA’s BioNeMo platform. The objective is to allow researchers to ask natural-language scientific questions across biomedical knowledge graphs while maintaining a transparent connection to underlying scientific evidence.
Nitin Sood, senior vice president and head of product portfolio and innovation at QIAGEN, said the collaboration builds on more than 25 years of curated biomedical knowledge developed by QIAGEN Digital Insights.
Sood said combining this scientific foundation with advanced AI technologies could improve key areas of drug discovery, including therapeutic target identification, biomarker research and scientific hypothesis generation.
The collaboration is expected to support a range of applications across the pharmaceutical research pipeline, including target validation, drug repurposing, pathway analysis and biomarker discovery using multi-omics data.
QIAGEN said its biomedical knowledge bases currently support more than 150,000 scientists worldwide and are informed by over 70,000 scientific publications. The platform organizes information across genes, diseases, pathways, compounds, clinical insights and more than 30,000 diseases to help researchers evaluate whether AI-generated findings are biologically plausible, novel and relevant.
Initial pilot programs involving the new AI-enabled capabilities will be launched with selected pharmaceutical and biotechnology partners before broader commercialization. The companies said wider availability of the technology is expected after validation studies are completed.
The partnership underscores growing interest in combining generative AI, biomedical databases and accelerated computing infrastructure to shorten drug discovery timelines and improve the reliability of scientific decision-making in pharmaceutical research.